Venezuela IVD Registration Pathway: Performance Evidence and Dossier Design

1. Key takeaways

In vitro diagnostic reagents (IVD) are regulated by SACS in Venezuela together with medical devices, but they carry additional documentation requirements. Beyond the general dossier, a performance evaluation report must be submitted, together with explanations covering the qualitative or quantitative attributes of the test method, the degree of automation, and the sample collection procedure.

The conclusion is that IVD performance data is the single largest source of requests for information in Venezuelan review, and the reason is structural: the evidence takes a different form from that of therapeutic devices. The core evidence for an IVD is analytical and clinical performance data, not biocompatibility or electrical safety data. Applying a therapeutic device template to an IVD therefore guarantees gaps, and those gaps are discovered at the point in the process where correction is slowest.

The practical consequence is that an IVD file should be written from the analytical question backwards. What is being measured, by what method, in what kind of sample, and with what demonstrated performance at the claimed decision point. A file organized around those four questions tends to survive review; a file organized around the structure of a device submission tends to generate correspondence.

2. Legal basis

Basis of the figures: the additional IVD documentation items listed in this section derive from descriptions of Venezuelan requirements in industry comparison material and are labeled practical estimate. The current list should be confirmed with the accepting office before the project is executed.

3. Expert insights

Insight 1: IVD evidence is tightly bound to the analyte and to the methodology. Different kits on the same platform cannot share performance data, because both the analyte and the method differ. This makes IVD family grouping follow different logic from therapeutic device grouping: the basis for grouping is the same methodology plus the same analyte category, not the same platform. A grouping built on platform identity will look coherent on the instrument side and fall apart in the performance section.

Insight 2: distinguishing qualitative, quantitative and semi-quantitative assays changes the required depth of data. A quantitative reagent needs 5 categories of analytical performance data — linear range, limit of detection, limit of quantification, accuracy and precision. A qualitative reagent leans instead on agreement rate and cut-off verification. If the file does not make this distinction clear, the reviewer cannot judge whether the data provided is sufficient, and the default response in that situation is a request for more.

Insight 3: stability data carries more weight in IVD than in most therapeutic devices. Shelf life, open-vial stability and transport stability all bear directly on the test result, and Venezuelan climatic and logistics conditions make transport validation more necessary than in temperate markets (see Article 29). A stability package copied from a European submission without revisiting transport conditions is a predictable source of questions.

A related point concerns intended use statements. IVD intended use is often written at a level of generality that the performance data cannot support — for example, claiming suitability across sample types when validation covered serum only. Narrowing the claim to what was actually validated is usually faster than expanding the validation, and it is the adjustment most often skipped because it reduces the commercial scope of the registration.

There is also an ordering question inside the performance report itself. Analytical performance establishes whether the assay behaves as claimed in a controlled setting; clinical performance establishes whether that behaviour translates into a useful result in the intended population. Reviewers read them in that order, and a report that presents clinical conclusions without the analytical foundation underneath invites the question of what the conclusions rest on. Sequencing the sections to match the logic of the argument costs nothing and removes an entire category of follow-up.

Cut-off definition deserves particular attention in qualitative assays, because the cut-off is where clinical utility is decided. A file that states a cut-off without showing how it was established, and without showing what happens to results immediately on either side of it, leaves the central claim of the product unsubstantiated. The supporting evidence is usually a method comparison or a receiver operating characteristic analysis, and it must be presented as evidence of a decision rather than as a statistical appendix.

For semi-quantitative assays the corresponding risk is category boundary ambiguity. Results are reported in bands, and the boundaries between bands require the same justification as a single cut-off. Where a submission describes only the analytical range and omits the band definitions, the reviewer has no basis for assessing whether the reported categories correspond to the intended clinical interpretation.

4. Practical recommendations

1. Build a dedicated template for IVD dossiers and do not reuse the therapeutic device template. At a minimum it should cover the methodology description, for example enzyme-linked immunosorbent assay, immunochromatography or chemiluminescence; the qualitative or quantitative attribute; manual, automated or semi-automated mode of use; the target indication and the intended user.
2. Divide the performance evaluation report into analytical performance and clinical performance sections, each listing sample source, sample size, statistical method and conclusion, so that sufficiency can be assessed section by section.
3. Submit the sample collection procedure as a standalone chapter, covering collection, handling, storage conditions and rejection criteria.
4. Submit stability data separately for real-time stability and transport stability, with the transport study reflecting the actual logistics conditions of the Venezuelan route rather than a generic profile.

5. Verification checklist

• □ The IVD dossier uses a dedicated template and does not follow the therapeutic device structure
• □ Methodology, qualitative or quantitative attribute and degree of automation are explicitly stated
• □ Analytical and clinical performance data are complete and separately sectioned, with traceable statistical methods
• □ The sample collection procedure is a standalone chapter and includes rejection criteria
• □ Stability data covers both real-time and transport conditions, with transport conditions reflecting local practice

Regulatory information verified as of October 29, 2026.

GRZAN provides registration support in Venezuela for manufacturers, importers and authorized representatives, covering IVD dossier structuring, performance evaluation documentation and stability package review. For scope and document requirements, contact info@grzanglobal.com.